BioSpace News Archive

OnQuality Pharmaceuticals (“OnQuality”), today announced that Part 1 of the Phase 2 NOVA-II clinical trial evaluating OQL011 met the company’s expectations of safety, efficacy and the patient reported outcome of Hand-Foot Skin Reaction (HFSR)-related pain.

IVERIC bio, Inc. announced that Pravin U. Dugel, M.D., President, will present an overview of the Company at the H.C. Wainwright BioConnect Virtual Conference, being held virtually from January 10-13, 2022.

Axcella Therapeutics, a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabolic modulator compositions, announced that President and Chief Executive Officer Bill Hinshaw will be presenting at the H.C. Wainwright BioConnect Conference.

Savara Inc., a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will present at the H.C. Wainwright BIOCONNECT Virtual Conference being held January 10-13, 2022.

Exelixis, Inc. announced the appointment of Vicki L. Goodman, M.D., as Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer.

Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, announces that Michael Nall, President and CEO, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022.

Amylyx Pharmaceuticals, Inc. today announced it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for AMX0035 (sodium phenylbutyrate (PB) and ursodoxicoltaurine (TURSO; also known as taurursodiol)) for the treatment of amyotrophic lateral sclerosis (ALS).

LENSAR, Inc., a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, announced Nick Curtis, Chief Executive Officer, will present at the H.C. Wainwright Virtual BioConnect Conference.

Ray Therapeutics, a biotech company developing optogenetic gene therapies for patients with blinding diseases, today announced the closing of a $6M seed financing round, led by 4BIO Capital.

Ocular Therapeutix, Inc. (Nasdaq: OCUL) a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright BioConnect 2022 Virtual Conference being held January 10-13, 2022.